12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Latuda lurasidone regulatory update

FDA approved an sNDA from Dainippon's Sunovion Pharmaceuticals Inc. subsidiary to expand the recommended dose range of Latuda lurasidone to include once-daily 120 and 160 mg/day and to include a 120 mg tablet formulation of the schizophrenia...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >